-+ 0.00%
-+ 0.00%
-+ 0.00%

Erasca sees ERAS-0015 Phase 1 monotherapy data by mid-May 2026

PUBT·04/21/2026 13:11:05
Listen to the news
Erasca sees ERAS-0015 Phase 1 monotherapy data by mid-May 2026
  • Erasca narrowed timing for Phase 1 monotherapy data readout for pan-RAS molecular glue ERAS-0015 to no later than mid-May 2026.
  • Results have not yet been presented; data are expected in the future, replacing prior guidance for a readout in first half of 2026.
  • Readout is expected to inform early view on whether ERAS-0015 shows initial signs of activity as a standalone treatment in RAS-mutant solid tumors.
  • ERAS-0015 is being tested in Erasca’s AURORAS-1 Phase 1 trial, with a parallel China study run by licensor Guangzhou Joyo Pharmatech in advanced solid tumors with specific RAS mutations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-165297), on April 21, 2026, and is solely responsible for the information contained therein.